Marko is a structural biochemist with over 20 years of experience in producing complex proteins for structural analysis. He studied biochemistry at the University of Helsinki and did his PhD at European Molecular Biology Laboratory in Heidelberg. He joined the Department of Biochemistry in Cambridge in 1998 and has been leading a research group since 2001. One of the main themes in his research is to understand the structure and function of TGF-beta family growth factors, with particular focus on activins. He runs a core facility providing high quality growth factors and other protein-based tools for stem cell research consortium at the University of Cambridge and this expertise is part of the foundations of Qkine.
A biochemist with academic and commercial experience, Catherine earned her PhD in platelet biology from the University of Cambridge. In 2003, she joined Abcam and under her leadership, the in-house laboratory responsible for antibody design, manufacture and characterisation grew from 4 to 40 staff. She assisted with a successful IPO on AIM in 2005 and was a member of the senior management team. She returned to academic research in 2015 and was awarded a Daphne Jackson fellowship at the Wellcome Sanger Institute where she studied the role of surface proteins in parasite infection. She co-founded Qkine in 2016 to address challenges in the growth factor supply chain and support innovations in stem cell science and regenerative medicine.
Jim graduated from Christ’s College Cambridge in 1986 with a degree in computer science and joined Analysys Limited, a Cambridge-based telecommunications consultancy where he headed up its IT, software and web development initiatives. Analysys Managing Director, David Cleevely, was one of the founders of Abcam and Jim moved to join them in 2000 as a Technical Director focussing on building a scalable e-commerce architecture for the startup. He took over the operational management of the UK office as Managing Director in June 2004, working on both Abcam’s growth plans as well as efficiency improvement programmes. In 2009, Jim became Chief Operating Officer, with responsibility for overseeing the operational strategy of the Group. Jim left Abcam at the end of 2016 and presently, outside of Qkine, is a NED for a couple of other Cambridge companys – the startup Cambridge Nutraceuticals Limited and the AIM listed Quartix Plc. Jim is also chairs the multi-academy trust, the Cambridgeshire Educational Trust.
Rob graduated from Pembroke College, Oxford in 1987 with a degree in chemistry, and then went on to complete his D.Phil studying new materials with applications in non-linear optics and optical information storage. He then joined Oxford Molecular Limited, an Oxford spin-out company developing computational chemistry software applications. Over a 7 year career with OM, Rob worked his way up from junior software developer to being head of external collaborations, working with a group of large Pharma clients on innovative software solutions to drug discovery challenges. In 1998, Rob joined CambridgeSoft Inc with the remit of creating a European division for them. As VP of European Operations, Rob was responsible, over the next 12 years, for the growth of a $20m business. Rob left CambridgeSoft at the beginning of 2010 to become CEO of Cresset, a growing Cambridge-based computational chemistry software and services company.